268 related articles for article (PubMed ID: 32719484)
1. Population genetic screening efficiently identifies carriers of autosomal dominant diseases.
Grzymski JJ; Elhanan G; Morales Rosado JA; Smith E; Schlauch KA; Read R; Rowan C; Slotnick N; Dabe S; Metcalf WJ; Lipp B; Reed H; Sharma L; Levin E; Kao J; Rashkin M; Bowes J; Dunaway K; Slonim A; Washington N; Ferber M; Bolze A; Lu JT
Nat Med; 2020 Aug; 26(8):1235-1239. PubMed ID: 32719484
[TBL] [Abstract][Full Text] [Related]
2. Association of Rare Pathogenic DNA Variants for Familial Hypercholesterolemia, Hereditary Breast and Ovarian Cancer Syndrome, and Lynch Syndrome With Disease Risk in Adults According to Family History.
Patel AP; Wang M; Fahed AC; Mason-Suares H; Brockman D; Pelletier R; Amr S; Machini K; Hawley M; Witkowski L; Koch C; Philippakis A; Cassa CA; Ellinor PT; Kathiresan S; Ng K; Lebo M; Khera AV
JAMA Netw Open; 2020 Apr; 3(4):e203959. PubMed ID: 32347951
[TBL] [Abstract][Full Text] [Related]
3. Aligning policy to promote cascade genetic screening for prevention and early diagnosis of heritable diseases.
George R; Kovak K; Cox SL
J Genet Couns; 2015 Jun; 24(3):388-99. PubMed ID: 25577298
[TBL] [Abstract][Full Text] [Related]
4. The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice.
Menko FH; Ter Stege JA; van der Kolk LE; Jeanson KN; Schats W; Moha DA; Bleiker EMA
Fam Cancer; 2019 Jan; 18(1):127-135. PubMed ID: 29846880
[TBL] [Abstract][Full Text] [Related]
5. Genetic counselors' perspectives on population-based screening for BRCA-related hereditary breast and ovarian cancer and Lynch syndrome.
De Simone LM; Arjunan A; Vogel Postula KJ; Maga T; Bucheit LA
J Genet Couns; 2021 Feb; 30(1):158-169. PubMed ID: 32562467
[TBL] [Abstract][Full Text] [Related]
6. Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes.
Beebe-Dimmer JL; Kapron AL; Fraser AM; Smith KR; Cooney KA
J Clin Oncol; 2020 Jun; 38(16):1807-1813. PubMed ID: 32208047
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of a genomic screening program for actionable genetic conditions.
Buchanan AH; Lester Kirchner H; Schwartz MLB; Kelly MA; Schmidlen T; Jones LK; Hallquist MLG; Rocha H; Betts M; Schwiter R; Butry L; Lazzeri AL; Frisbie LR; Rahm AK; Hao J; Willard HF; Martin CL; Ledbetter DH; Williams MS; Sturm AC
Genet Med; 2020 Nov; 22(11):1874-1882. PubMed ID: 32601386
[TBL] [Abstract][Full Text] [Related]
8. Population-based genetic testing for Women's cancer prevention.
Evans O; Gaba F; Manchanda R
Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():139-153. PubMed ID: 32245629
[TBL] [Abstract][Full Text] [Related]
9. Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy.
Dudley B; Karloski E; Monzon FA; Singhi AD; Lincoln SE; Bahary N; Brand RE
Cancer; 2018 Apr; 124(8):1691-1700. PubMed ID: 29360161
[TBL] [Abstract][Full Text] [Related]
10. Hereditary cancer-associated mutations in women diagnosed with two primary cancers: an opportunity to identify hereditary cancer syndromes after the first cancer diagnosis.
Saam J; Moyes K; Landon M; Williams K; Kaldate RR; Arnell C; Wenstrup R
Oncology; 2015; 88(4):226-33. PubMed ID: 25503195
[TBL] [Abstract][Full Text] [Related]
11. Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility.
Rowley SM; Mascarenhas L; Devereux L; Li N; Amarasinghe KC; Zethoven M; Lee JEA; Lewis A; Morgan JA; Limb S; Young MA; James PA; Trainer AH; Campbell IG
Genet Med; 2019 Apr; 21(4):913-922. PubMed ID: 30254378
[TBL] [Abstract][Full Text] [Related]
12. Ovarian Cancer in Hereditary Cancer Susceptibility Syndromes.
Nakonechny QB; Gilks CB
Surg Pathol Clin; 2016 Jun; 9(2):189-99. PubMed ID: 27241103
[TBL] [Abstract][Full Text] [Related]
13. Challenges in the diagnosis and management of Lynch Syndrome in an Indigenous family living in a remote West Australian community.
Schofield L; Goldblatt J; Iacopetta B
Rural Remote Health; 2011; 11(4):1836. PubMed ID: 22188021
[TBL] [Abstract][Full Text] [Related]
14. Scoping the family history: assessment of Lynch syndrome (hereditary nonpolyposis colorectal cancer) in primary care settings--a primer for nurse practitioners.
Maradiegue A; Jasperson K; Edwards QT; Lowstuter K; Weitzel J
J Am Acad Nurse Pract; 2008 Feb; 20(2):76-84. PubMed ID: 18271762
[TBL] [Abstract][Full Text] [Related]
15. Underdiagnosis of Hereditary Breast and Ovarian Cancer in Medicare Patients: Genetic Testing Criteria Miss the Mark.
Yang S; Axilbund JE; O'Leary E; Michalski ST; Evans R; Lincoln SE; Esplin ED; Nussbaum RL
Ann Surg Oncol; 2018 Oct; 25(10):2925-2931. PubMed ID: 29998407
[TBL] [Abstract][Full Text] [Related]
16. Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes.
Manchanda R; Burnell M; Gaba F; Desai R; Wardle J; Gessler S; Side L; Sanderson S; Loggenberg K; Brady AF; Dorkins H; Wallis Y; Chapman C; Jacobs C; Legood R; Beller U; Tomlinson I; Menon U; Jacobs I
BJOG; 2020 Feb; 127(3):364-375. PubMed ID: 31507061
[TBL] [Abstract][Full Text] [Related]
17. Improving the uptake of predictive testing and colorectal screening in Lynch syndrome: a regional primary care survey.
Barrow P; Green K; Clancy T; Lalloo F; Hill J; Evans DG
Clin Genet; 2015 Jun; 87(6):517-24. PubMed ID: 25652327
[TBL] [Abstract][Full Text] [Related]
18. Patients Tested at a Laboratory for Hereditary Cancer Syndromes Show an Overlap for Multiple Syndromes in Their Personal and Familial Cancer Histories.
Saam J; Arnell C; Theisen A; Moyes K; Marino I; Roundy KM; Wenstrup RJ
Oncology; 2015; 89(5):288-93. PubMed ID: 26315041
[TBL] [Abstract][Full Text] [Related]
19. Singapore Cancer Network (SCAN) Guidelines for Referral for Genetic Evaluation of Common Hereditary Cancer Syndromes.
Singapore Cancer Network (SCAN) Cancer Genetics Workgroup
Ann Acad Med Singap; 2015 Oct; 44(10):492-510. PubMed ID: 26763067
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
